Vera Therapeutics Reports the Initiation of Atacicept in the P-III Trial (ORIGIN 3) for the Treatment of IgA Nephropathy
Shots:
- The company initiates the P-III trial of atacicept (150mg, qw, SC) vs PBO in a ratio (1:1) in 376 patients for 104wks., followed by a 52wk. open-label extension
- The 1EPs of the trial is the change in proteinuria as evaluated by UPCR @36wk. while the 2EPs is an annualized rate of change in eGFR up to 104wk. and change in Gd-IgA1 & eGFR up to 52wk. along with time from randomization to the first occurrence of composite kidney failure endpoint event. The results will be presented at ERA 2023
- Atacicept, a disease-modifying dual inhibitor of the cytokines BLyS & a proliferation-inducing ligand (APRIL). The P-IIb trial (ORIGIN) of atacicept showed a reduction in mean proteinuria vs baseline @24wks.
Ref: Globe Newswire | Image: Vera
Related News:- Vera Seeks to Initiate P-III Clinical Trial of Atacicept for the Treatment of Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
